GESA AGW

Professor Paolo Angeli 

Prof. Paolo Angeli is Full Professor of Internal Medicine. He is the head of Unit of Internal Medicine and Hepatology (UIMH) of the University of Padova (Italy). He leads a research group working on the pathophysiology and treatment of acute, chronic and acute on chronic liver failure and on liver transplantation. He was the secretary of the International Club of Ascites from 2010 up to April 2018. From January 2018 he is the Chair of the EASL-Clif Consortium. From 2010 he was an Associate Editor of the Journal of Hepatology and from July 2019 he has become the Editor in Chief of the Journal. He is author of more than 300 papers on international journals with peer review, cited by JCR. He has contributed to the guidelines and/or positional papers on the management of ascites, bacterial infections and acute renal injury (AKI) and Acute on Chronic Liver Failure (ACLF) in patients with cirrhosis for the European Association for the Study of the Liver. He has contributed to the new diagnostic criteria for AKI in patients with cirrhosis as a result of a consensus process with almost all the international experts in this field.

(Sun 08:30-10:00) Mezzanine 4 Session 1 Advanced Liver Disease
(08:30-08:50) Albumin in Cirrhosis – From Ambulatory Care to ACLF
(09:20-09:50) From the Editor’s Desk: the Future of Hepatology

Dr. Dustin Carlson MD, MS

Dr. Carlson is an Assistant Professor of Medicine in Gastroenterology at Northwestern University Feinberg School of Medicine.  He is the Director of the Esophageal Center of Northwestern as well as the Director of the Motts Tonelli Esophageal Function Lab of Northwestern Medicine. He a member of the International High Resolution Manometry Working Group, acting chair of the International FLIP Panometry working group, and active member on ACG and AGA committees.  His clinical and research interests are on benign esophageal diseases (achalasia, esophageal motility disorders, and gastroesophageal reflux disease, EoE), on which he has authored over 130 peer-reviewed publications. 

(Mon 08:30-10:00) Great Hall Session 1 General GE: Upper Clinical Motility
(08:30-09:00) Personalizing Treatment in GERD

(Mon 16:00-17:30) Great Hall Session 4 State-of-the-Art General GE: Dysphagia and AGM
(16:00-16:25) State-of-the-Art: Approach to Non Achalasia Dysphagia

(Tue 12:30-14:30) Mezzanine 3 Chairing Session 2 General GE: Lower or Small Bowel Motility Session

Dr. Noa Krugliak Cleveland

Dr. Krugliak Cleveland is an assistant professor and the director of the intestinal ultrasound program at the University of Chicago. She is an expert in intestinal ultrasound and a leader in dissemination of this technology in North America, a cofounder of the Intestinal Ultrasound Group of the United States and Canada (iUSCAN) and an active committee member of the international Bowel Ultrasound Group (IBUS).

Dr. Krugliak Cleveland investigates the application of new technology for the detection and prevention of complications of IBD including neoplasia and ulcerative colitis as a progressive disease. Her original scholarship has been published in Gastroenterology, The American Journal of Gastroenterology, Inflammatory Bowel Diseases, Clinical Gastroenterology and Hepatology, Digestive Diseases and Sciences. 

(Sun 13:30-15:30) Plaza 1&2 Session 3 GENIUS Advanced IUS Forum with Live Demonstration
(14:30-14:45) Crohn’s Disease Complications – Strictures and Abscess

(Mon 08:30-10:00) Mezzanine 3 Session 1 IBD: GENIUS
(08:30-08:45) Integrating IUS into IBD Training and Practice in The USA

Dr. Ana Dugic

Dr. Ana Dugic is a Gastroenterology Fellow at Heidelberg University Hospital, Heidelberg, Germany. She is a Research Fellow in Pancreatology at Karolinska Institute, Stockholm, Sweden. Her clinical and research activities focus on endoscopy and pancreatic diseases, including pancreatic cancer screening, pancreatic cysts, inflammatory disorders of the pancreas, and pancreatogenic diabetes.

Dr. Dugic is involved in undergraduate and postgraduate teaching and passionate about ongoing research. She serves as a Trainee Editor of UEG Journal and is a board member of the Young Talent Group of the United European Gastroenterology (UEG). She is also a member of the UEG Public Affairs Committee, a board member of the Young Gastroenterology of the German Society for Digestive and Metabolic Diseases (DGVS), and a member of the European Society of Gastrointestinal Endoscopy (ESGE), the American Society for Endoscopy (ASGE), and the Gastroenterological Society of Australia (GESA).

(Mon 16:00-17:30) Mezzanine 3 Session 4 Young GESA
(16:15-16:35) Connecting Continents: UEG Young GI Network Update and Quest for Collaborative Endeavours with Young GESA

Dr. Gideon Hirschfield

World-renowned autoimmune liver disease clinician-researcher, Dr. Gideon Hirschfield has been successfully recruited to the Toronto Centre for Liver Disease (TCLD) at UHN. Dr. Hirschfield is the inaugural Lily and Terry Horner Chair in Autoimmune Liver Disease Research at the TCLD, Toronto General Hospital and Professor of Medicine in the Division of Gastroenterology at the University of Toronto.

Dr. Hirschfield has extensive clinical expertise in the management of complex liver disease, pre- and post-transplant, and is now leading the Autoimmune Liver Disease Program at TCLD. This comprehensive program offers life-long care to patients with autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, while advancing groundbreaking research.

As a clinician-scientist Dr. Hirschfield manages a broad platform of translational and trials based clinical science with the goal of advancing therapies for patients with inflammatory liver disease that prevent the need for transplantation.

Dr. Hirschfield is the recipient of many international awards and is a global key opinion leader in autoimmune liver disease. He has published over 200 papers, among which include publications as the lead author in the high-impact scientific journals.

Source: https://uhnfoundation.ca/stories/world-renowned-autoimmune-liver-disease-clinician-researcher-recruited-to-the-toronto-centre-for-liver-disease/

(Mon 16:00-17:30) Mezzanine 1&2 Session 4 Autoimmune Liver Disease
(16:00-16:30) State Of The Art: Management of Autoimmune Hepatitis In 2023

(16:30-16:44) Urso In Beneficial In PSC – AFFIRMATIVE/NEGATIVE 
16:44-16:50 Verdict

A/Prof. Vera Meeusen

Bio to come …

(Mon 08:00-10:00) Mezzanine 4 Session 1 Sustainability
(08:25-08:50) Practical Implementation of Sustainability in Endoscopy Unit – Australian Experience

Professor Phil Newsome

Professor of Hepatology, University of Birmingham
Director of Research & Knowledge Transfer at College of Medical & Dental Sciences University of Birmingham
Director, Birmingham NIHR Biomedical Research Centre (BRC)

Professor Newsome runs the metabolic services at the Liver Unit at the Queen Elizabeth Hospital Birmingham which includes a large multi-disciplinary clinic for patients with NAFLD. He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapies in NAFLD published in the Lancet and the NEJM. He is the Co-ordinating Investigator for several global NAFLD studies. He chaired the national guidelines for liver transplantation in NAFLD and sat on the NICE Guideline Development Group for NAFLD. He led the recent UK multi-stakeholder guideline group on the management of abnormal liver blood tests and led on NAFLD for the recent EASL Lancet Liver Commission. He recently completed his term as Secretary General (President) of EASL.

(Mon 13:30-15:30) Great Hall Session 3 State-of-the-Art Liver: MAFLD & AGM
(13:30-14:00) Future Directions of MAFLD Therapy

Dr. Kimmie Ng

Associate Chief of the Division of Gastrointestinal Oncology at Dana-Farber Cancer Institute (DFCI), and Associate Professor of Medicine at Harvard Medical School. She also serves as Director of the Young-Onset Colorectal Cancer Center and Director of Translational Research in the division. Her research focuses on identifying dietary and molecular predictors of improved survival in patients with colorectal cancer, with a special interest in the vitamin D pathway and the microbiome. She is the recipient of numerous NIH, foundation, and industry grants, and recently chaired the American Society of Clinical Oncology (ASCO) Scientific Program Committee for the 2023 Annual Meeting. She has been featured in multiple national media outlets, including the TODAY Show, ABC News, The New York Times, CNN, and the Washington Post to raise awareness of young-onset colorectal cancer. Dr. Ng obtained her Bachelor of Science degree with Distinction from Yale University and her Doctor of Medicine degree from University of Pennsylvania Perelman School of Medicine. She completed a residency in internal medicine at University of California, San Francisco (UCSF) and a medical oncology fellowship at DFCI. She subsequently received a Master of Public Health degree from Harvard T.H. Chan School of Public Health.

(Sun 08:15-10:15) Mezzanine 1&2 Session 1 Private Practice Network
(08:15-08:55) The Current Bowel Cancer Screening Guidelines are no Longer Fit for Purpose – For and Against Discussion panel member

(Tue 09:00-10:45) Great Hall Session 1 State of the Art GI Cancer – Early Onset Colorectal Cancer
(09:00-09:30) Young-Onset Colorectal Cancer: Understanding the Rise

Dr. Mindie H. Nguyen

Dr. Mindie H. Nguyen is Professor of Medicine, and by courtesy, Professor of Epidemiology and Population Health, Director for the Hepatology Fellowship, Director for the Hepatology Clerkship, a Member of the Appointment and Promotion Committee, and a Diversity Advisor for the Department of Medicine at Stanford University Medical Center. She is an active clinician and researcher in viral hepatitis, NAFLD, and liver cancer with over 200 original research publications including first or senior authorship in The New England Journal of Medicine, Lancet Gastroenterology and Hepatology, Gastroenterology, Journal of Hepatology, Hepatology, and JAMA NO.  She has served as editorial/advisory board member for major journals such as Lancet Gastroenterology and Hepatology, Gastroenterology, and Hepatology. She has served as Chair of the Hepatitis B SIG for the AASLD. She has mentored over 130 trainees from high-school students to undergraduate, medical, Masters/PhD students in Public Health/Epidemiology, clinical residents/fellows, postdoctoral research fellows, and faculty at Assistant/Associate Professor rank.

(Mon 13:30-15:30) Great Hall Session 3 State-of-the-Art Liver: MAFLD & AGM
(14:00-14:20) MAFLD Complications: HCC and Implications for Liver Transplantation

Professor David Rubin

MD, FACG, AGAF, FACP, FASGE, FRCP (Edinburgh)
Joseph B. Kirsner Professor of Medicine; Chief, Section of Gastroenterology, Hepatology and Nutrition
University of Chicago Medicine, Chicago, IL

David T. Rubin is the Joseph B. Kirsner Professor of Medicine, Chief of the Section of Gastroenterology, Hepatology & Nutrition at the University of Chicago Medicine. He earned a medical degree with honors at The University of Chicago Pritzker School of Medicine where he also completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics. He is associate faculty member at the MacLean Center for Clinical Medical Ethics, associate investigator at the University of Chicago Comprehensive Cancer Center and a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation. He is the deputy chair of the Executive Committee of the International Organization for the Study of Inflammatory Bowel Disease.

Dr. Rubin twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), and in 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn’s and Colitis. He is an Associate Editor of the journal Gastroenterology and Editor-in-Chief of the ACG On-Line Education Universe. Dr. Rubin is an editor of Curbside Consultation in IBD (3^rd ed), senior editor of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease (12^th ed), and an author on >500 articles on management of IBD, including the 2019 ACG Guidelines for ulcerative colitis. He has a verified Twitter account @IBDMD with over 20,500 followers.

(Sun 16:00-17:30) Great Hall Charing Session 4 State-of-the-Art IBD: Sequencing & AGM
(16:00-16:30) Sequencing of Therapies | Small Molecules

(Mon 08:30-10:00) Mezzanine 3 Session 1 IBD: GENIUS
(08:55-09:10) Should Transmural Healing be a Current Treatment Aim in IBD?

(Tue 12:30-14:30) Great Hall Session 2 IBD – Monitoring & Modification
(12:30-12:50) Disease Modification in IBD: Stopping The Clock

Associate Professor Shintaro Sagami

Associate Professor Shintaro Sagami is a Research Physician and Medical Director at the Kitasato Institute Hospital, Japan. He is also a Councilor of the Japan Gastroenterological Endoscopy Society (JGES) and Japanese Gastroenterological Association (JGA). He received his MD at Kinki University, Japan and his PhD in Biomedical and Health Sciences at Hiroshima University, Japan. His research interests include Crohn’s disease, Ulcerative Colitis,  IBD and ultrasound in IBD, and has published over 100 papers in peer-reviewed journals, and his work has been presented at numerous international conferences . Associate Professor Sagami is also a recipient of Travel Awards from the Asian Organization for Crohn’s and Colitis (AOCC) and the European Crohn’s and Colitis Organization (ECCO).

(Sun 13:30-15:30) Plaza 1&2 Session 3 GENIUS Advanced IUS Forum with Live Demonstration
(13:30-13:45) Perineal Ultrasound for Fistulising Disease and Perianal Complications

(13:45-14:00) Live Demo – Fistula Assessment

(14:45-15:00) Live Demo – Stricture and Abscess Assessment

Detlef Schuppan

Detlef Schuppan received his MD degree in Berlin, and two PhD degrees in Germany. He was Associate Professor of Gastroenterology/Hepatology/Medicine in Berlin and Full Professor and Deputy Director of the Dept of Medicine I (Gastroenterology, Hepatology, Infectious Diseases, Endocrinology) at the University of Erlangen-Nuremberg, Germany until 2004.

He is has been Professor of Medicine, Gastroenterology and Hepatology and Consultant at Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School (HMS) in Boston.

Since 2011 he is Director of the Institute of Translational Immunology and Director of the Clinical Center for Celiac, Small Intestinal, Metabolic and Autoimmune Diseases at Mainz University Medical Center, maintaining his senior faculty position at BIDMC and HMS.

Research and clinical focus is on liver inflammation, fibrosis, celiac disease, atypical food allergies/IBS, the gut-liver axis, celiac disease, the role of the nutritional factors and the intestinal microbiome on autoimmunity, GI and liver cancer. Apart from the preclinical and clinical validation of novel therapeutics, including small molecules, siRNA and nanoparticles, his group develops novel noninvasive biomarkers and targeted imaging to predict and monitor the activity of these diseases.

DS has been and continues to be consultant, principal and co-Investigator in numerous clinical phase 1-3 trials in celiac disease, liver fibrosis, NASH, metabolic and autoimmune diseases. He has been and is in leading positions of major national international GI and liver associations, served and serves as editor of renowned journals in these fields, and received several international prizes. He has mentored and qualified more than 120 PhD and MD/PhD students. He has published more than 630 Pubmed cited original articles and reviews. He has >38,000 citations and an h-index of 100 (isi-web/pubmed); >64,000 citations and an H-index of 130 (google scholar).

(Sun 08:30-10:00) Mezzanine 4 Session 1 Advanced Liver Disease
(09:20-09:50) From the Editor’s Desk: the Future of Hepatology

(Mon 16:00-17:30) Mezzanine 1&2 Session 4 Autoimmune Liver Disease
(16:50-17:05) PSC And Diet: What Should I Eat, Doc?

(Tue 12:30-14:30) Mezzanine 3 Session 2 General GE: Lower or Small Bowel Motility Session
(12:30-12:50) Novel Developments In Coeliac Disease

Dr. William Stableforth

William is a consultant Hepatologist, Gastroenterologist and Physician with a special interest in the interaction between climate and health. He is a founder member of the International Green endoscopy network and the Sustainable Hepatology Group. He is chair of the Sustainable Hepatology working group within the British Association for the study of the liver (BASL) and a member of the Royal College of Physicians (RCP) advisory group of sustainability healthcare and climate. William has a background in climate activitism and is an active member of Doctors for Extinction Rebellion.

(Mon 08:00-10:00) Mezzanine 4 Session 1 Sustainability
(08:05-08:25) Climate Change and Liver Healthcare

Professor Holm Uhlig

Professor Uhlig is an investigator in the Translational Gastroenterology Unit, University of Oxford and Honorary Consultant in Pediatric Gastroenterology, Children’s Hospital Oxford. As a pediatrician, Holm has developed a strong interest in supporting patients with primary immunodeficiency and monogenic forms of inflammatory bowel disease. As a research focus, he investigates the genetic and immunologic basis of disorders associated with intestinal inflammation aiming to understand functional mechanisms that contribute to autoimmunity, tissue inflammation and disturbed barrier function. Holm Uhlig leads on the UK Paediatric IBD bioresource project and the COLORS in IBD project.

(Sun 13:30-tbc) Mezzanine 1&2 Session 3 State-of-the-Art Paediatrics & AGM
(13:30-14:15) Monogenic Inflammatory Bowel Disease: Ready for the Era of Personalised Medicine?

Dr. Shyam Varadarajulu, MD

Dr. Varadarajulu serves as the President of the Orlando Health Digestive Health Institute and is a Professor of Medicine at the University of Central Florida College of Medicine. Internationally known for his expertise and research in complex gastrointestinal disorders, Shyam Varadarajulu, MD is American Board certified in gastroenterology and specializes in treating pancreatic and biliary disorders with particular expertise in endoscopic ultrasound (EUS), therapeutic endoscopic retrograde cholangiopancreatography (ERCP), and luminal interventions.

Dr. Varadarajulu earned his medical degree from Madras Medical College in India, completed his internship and residency at St. Mary’s Hospital in Rochester, New York, gastroenterology fellowship at the University of Connecticut Heath Center in Farmington where he officiated as Chief Fellow, and interventional endoscopy fellowship at the Medical University of South Carolina in Charleston under the tutelage of Drs. Peter Cotton and Robert Hawes.  He was a former Chief of Endoscopy and Associate Professor of Medicine and Pediatrics at the University of Alabama at Birmingham (UAB) School of Medicine.

He has been the principal investigator of more than 20 randomized trials related to interventional endoscopy, including a study comparing EUS and ERCP for drainage in malignant biliary obstruction, and he has lectured and held visiting professorships around the world. Dr. Varadarajulu has authored 65 chapters in reference textbooks, and more than 300 peer-reviewed manuscripts in high impact journals. In addition, he is the editor of the textbook ENDOSONOGRAPHY, former section editor for the Clinical Gastroenterology and Hepatology, and Deputy editor-in-chief of Digestive Endoscopy.

(Sun 13:30-15:30) Great Hall. Chairing Session 3 State-of-the-Art: The Endoscopic Future
(14:55-14:20) Interventional Pancreatico-biliary Endoscopy – Innovations for Now and the Future

(Mon 16:00-18:00) Mezzanine 4. Chairing Session 4 Endoscopy: Pancreatobiliary and Duodenal
(17:25-17:45) APFC And WON – State Of The Art